This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| TREAT-NMD | |
|---|---|
| Name | TREAT-NMD |
| Formation | 2007 |
| Type | International network |
| Headquarters | Newcastle upon Tyne |
| Region served | Global |
TREAT-NMD TREAT-NMD is an international network focused on accelerating therapeutic development for neuromuscular disorders through collaboration among clinicians, researchers, patient organizations, industry, and regulatory bodies. It brings together expertise from academic institutions, pharmaceutical companies, patient advocacy groups, and health agencies to harmonize standards, support clinical trials, and develop patient registries. The network operates across Europe, North America, Australasia, and other regions, linking specialist centers in neuromuscular medicine and allied disciplines.
TREAT-NMD was launched in 2007 following discussions involving stakeholders from European Commission, Wellcome Trust, Medical Research Council (United Kingdom), and specialist centres such as Newcastle upon Tyne Hospitals NHS Foundation Trust and Great Ormond Street Hospital. Early collaborators included leading investigators from University College London, King's College London, University of Oxford, and Karolinska Institutet, alongside patient organizations like Muscular Dystrophy Campaign, Muscular Dystrophy Association (United States), and Parent Project Muscular Dystrophy. Over time, the initiative expanded through interactions with regulators including the European Medicines Agency, funders such as the National Institutes of Health, and academic hubs like Columbia University, Johns Hopkins University, and Stanford University.
Governance of the network has involved advisory and steering mechanisms drawing representatives from academic centres like University of Cambridge, industry partners such as Pfizer and GlaxoSmithKline, and patient organizations including EURORDIS-Rare Diseases Europe and AIM (Association Internationale. The operational structure has included coordinating centres located in institutions such as Newcastle University and collaborating hubs at Intermountain Healthcare and Telethon Foundation. Oversight has engaged ethics committees linked to institutions like Imperial College London and regulatory liaisons with agencies such as the Food and Drug Administration.
Key objectives encompass harmonizing outcome measures across centres like Great Ormond Street Hospital, establishing natural history cohorts with partners such as Mayo Clinic, facilitating biomarker discovery alongside groups at Scripps Research Institute, and supporting therapeutic development with industry collaborators such as Roche and Sarepta Therapeutics. Activities have included development of standard operating procedures used by centres including Vanderbilt University Medical Center and training programmes delivered with academic partners like University of Edinburgh and McGill University.
The network created formal collaborations with patient advocacy organizations including Muscular Dystrophy UK, Aldeas Infantiles, and Duchenne UK, research consortia at INSERM, CNRS, and NIH Clinical Center, and pharmaceutical partners including Novartis and Bayer. It interfaced with global initiatives such as International Rare Diseases Research Consortium and clinical research networks at European Organisation for Research and Treatment of Cancer and national rare disease registries coordinated by bodies like Health Canada and Agence Nationale de Santé Publique.
TREAT-NMD supported creation and curation of disease-specific registries in collaboration with centres such as Nationwide Children's Hospital, Baylor College of Medicine, and advocacy groups like Duchenne Parent Project Netherlands. Research initiatives included multicentre natural history studies with teams at University of Milan, biomarker validation projects with laboratories at Max Planck Institute, and genotype-phenotype databases linked to resources like ClinVar and the Human Gene Mutation Database. The network fostered data-sharing agreements engaging institutions like Harvard Medical School, Yale School of Medicine, and University of Washington.
The network developed trial-ready infrastructures by standardizing outcome measures used in trials conducted at sites such as Children's Hospital of Philadelphia and Hospital for Sick Children (Toronto), aligning protocols with regulatory guidance from European Medicines Agency and Food and Drug Administration, and providing site readiness assessments analogous to practices at Mayo Clinic. It promoted use of consensus standards produced with input from academic groups at University of California, San Francisco and industry sponsors including Astellas Pharma', and supported adaptive trial designs similar to those advanced by Adaptive Designs Working Group.
TREAT-NMD has influenced approval pathways and accelerated development programs that engaged companies such as Sarepta Therapeutics and academic spin-outs from University of Oxford and University College London. Outreach included educational workshops held at venues such as Royal Society and conferences like World Muscle Society and American Academy of Neurology, and engagement with policymakers from European Parliament and national health technology assessment agencies. The network's legacy includes strengthened links among centres such as Newcastle upon Tyne Hospitals NHS Foundation Trust, expanded patient registries across continents, and a model for collaborative translational research adopted by consortia associated with Alzheimer's Association and Cystic Fibrosis Foundation.